FDA Approves Olumiant for Alopecia Areata in Patients 12 and Older

Key Takeaways

• FDA approved Olumiant (baricitinib) for severe alopecia areata in adults and pediatric patients aged 12 years and older.
• FDA found the adolescent pediatric study requirement and its associated postmarketing obligation fulfilled.
• The approval decision does not provide measured trial efficacy or safety outcomes.
• Other postmarketing requirements from earlier Olumiant approvals remain open.

Adolescents with severe alopecia areata raise separate questions about treatment eligibility and use-specific details when an indication changes. For these patients, the indication defines who is eligible, while agreed-upon labeling supplies instructions for use. Federal review encompassed a supplemental application and an adolescent study obligation.

The Food and Drug Administration (FDA) reviewed a Prior Approval supplemental new drug application (NDA), NDA 207924/S-009, for Olumiant (baricitinib) tablets, dated and received December 2, 2025, under section 505(b) of the Federal Food, Drug, and Cosmetic Act. FDA's correspondence records a regulatory decision, not a publication of trial results. Postmarketing requirement 4289-1 called for a randomized controlled trial evaluating safety, efficacy, and pharmacokinetics in adolescents aged 12 to less than 18 years with severe alopecia areata. It required at least 300 subjects exposed to baricitinib for a minimum of 52 weeks; those were thresholds, not reported enrollment, completed follow-up, or clinical outcomes.

FDA approved the Olumiant supplemental indication for severe alopecia areata in adults and pediatric patients aged 12 years and older, effective September 25, 2026, the electronically signed letter date. The authorized use is as recommended in the agreed-upon labeling. Separately, FDA stated that the pediatric study requirement for ages 12 to less than 18 years was fulfilled and concluded that adolescent postmarketing requirement 4289-1 was fulfilled. These determinations concern regulatory obligations rather than measured trial endpoints.

Other postmarketing requirements established through earlier Olumiant approvals remain open. FDA also directed administrative follow-up: structured product labeling (SPL) is due as soon as possible and no later than 14 days after the letter, while amendments to pending supplemental applications involving labeling changes are also due within 14 days. Those deadlines do not establish that revised labeling has already been submitted or posted.

Adolescents with severe alopecia areata are included in the authorized treatment population for baricitinib. This regulatory decision does not itself supply clinical-outcome estimates.

Clinician Questions

Which earlier Olumiant approvals still have open postmarketing requirements after the adolescent alopecia areata decision?

FDA states that some Olumiant (baricitinib) postmarketing requirements from approval letters dated May 31, 2018, May 10, 2022, and June 13, 2022, remain open following its adolescent severe alopecia areata decision. FDA does not identify which individual requirements remain outstanding in that statement.

Will the updated Olumiant labeling for severe alopecia areata be publicly accessible?

FDA states that submitted SPL for Olumiant (baricitinib) in severe alopecia areata will be accessible through publicly available labeling repositories. Its required content corresponds to the agreed-upon Prescribing Information and Medication Guide, with applicable pending Changes Being Effected supplements and annual-reportable labeling changes added; that prospective access does not establish that an updated label is already online.